Last updated: February 15, 2026
What Is NDC 00555-0606?
NDC 00555-0606 identifies a specific pharmaceutical product. According to available data, it is a branded drug, with marketed formulations primarily used for anticoagulation. It corresponds to Eliquis (apixaban), a direct oral anticoagulant (DOAC) used in the treatment and prevention of thromboembolic events.
Key product features:
- Formulation: Tablets
- Strengths: Typically 2.5 mg and 5 mg doses
- Indications: Atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE)
- Manufacturer: Bristol-Myers Squibb and Pfizer
Market Landscape and Demand Drivers
Size of the Market
- The global anticoagulant market was valued at approximately $10 billion in 2022.
- The market for DOACs, including Eliquis, accounted for over 50% of this segment.
- Projected Compound Annual Growth Rate (CAGR): 6% from 2023-2028.
Key Demand Factors
- Increasing Atrial Fibrillation (AFib) prevalence, projected to reach 12 million in the U.S. by 2030.
- Growing awareness of stroke prevention strategies.
- Shift from warfarin to DOACs, driven by better safety profiles and convenience.
Competitive Environment
- Major competitors: Xarelto (rivaroxaban), Pradaxa (dabigatran).
- Eliquis holds a leading market share, about 35-40% of the DOAC segment.
- Patents and exclusivity rights extend until at least 2025–2027, influencing pricing power.
Pricing Dynamics
Current Price Benchmarks
- Wholesale Acquisition Cost (WAC): Approximately $450–$470 for a 30-tablet supply of 5 mg doses.
- Average Wholesale Price (AWP): Around $670–$700 for similar supply.
- Medicaid and Insurance Reimbursements: Negotiated discounts typically 20-25% below WAC.
Historical Price Trends
- Prices were stable until patent expiry discussions arose.
- Post-patent expiration of initial formulations in 2025, generic versions could reduce prices by 70–80%.
Price Projections (Next 5 Years)
| Year |
Estimated WAC (USD) |
Notes |
| 2023 |
$470 |
Current pre-patent expiry price |
| 2024 |
$470–$490 |
Slight increase for inflation and manufacturing costs |
| 2025 |
$350–$400 |
Patent expiry; generic entry expected |
| 2026 |
$150–$250 |
Generic competition increases; market shares shift |
| 2027 |
$100–$200 |
Further price drops as market stabilizes |
Note: These are estimates. Actual prices depend on regulatory decisions, insurance negotiations, and generic market penetration.
Regulatory and Policy Impact
- Patent exclusivity ends around 2025 for the primary formulation.
- Generic manufacturers approved shortly after patent expiry can Price reductions accelerate.
- Price negotiation trends in government programs (e.g., Medicaid, Medicare) influence retail prices and net prices.
Market Entry Barriers and Opportunities
Barriers:
- Established brand loyalty for Eliquis.
- Regulatory requirements for biosimilar approval.
- Patent litigation delaying generics.
Opportunities:
- Cost savings for payers with generics.
- Opportunities for biosimilar or alternative formulations.
- Expansion into emerging markets.
Summary of Investment and R&D Considerations
- Patent expiration (2025–2026) likely triggers a significant price decline.
- Existing market share provides a barrier to new entrants but offers a lucrative window pre-expiry.
- R&D investing in biosimilars or new formulations could leverage competitive advantages.
Key Takeaways
- NDC 00555-0606 (Eliquis) dominates a $10 billion anticoagulant segment projected to grow at 6% annually.
- The drug's pricing is currently around $470 WAC per 30 tablets; prices are expected to drop sharply post-2025 with generic entry.
- Patent expiration and biosimilar competition will significantly influence market share and prices over the next five years.
- Cost-effective alternatives and biosimilars are poised to reshape the market landscape, impacting drug pricing and profitability.
FAQs
1. When will generic versions of Eliquis become available?
Generic versions are expected to enter the market shortly after patent expiration, projected around 2025–2026.
2. How much could generic Eliquis cost initially?
Generic prices are typically 70–80% lower than brand-name prices, potentially around $150–$200 per 30-tablet supply.
3. What are the growth prospects for the anticoagulant market?
The global market is expected to grow at a CAGR of approximately 6% through 2028, driven by increasing prevalence of AFib and DVT.
4. How do insurance negotiations influence pricing?
Insurers and government programs negotiate discounts, reducing actual transaction prices below WAC or AWP benchmarks.
5. What are key strategies for pharmaceutical companies post-patent expiry?
Focus on biosimilar development, market differentiation, cost reductions, and expanding into emerging markets.
References
[1] Market research from IMARC Group, 2022.
[2] IQVIA, 2023.
[3] FDA drug approvals database, 2022.
[4] Pharma Intelligence, 2023.
